New Safety Information SOPs Committee Member

Training




Kim Brownley, Ph.D., IRB Chair Jeanne Lovmo, M.A., OHRE Compliance Manager




LEARNING OBJECTIVES

- What constitutes "new safety information"
- How is new safety information is processed within the OHRE







New or Increased Risk = New Safety Information

Adverse Events

- New findings
- Deviations
- Noncompliance







Adverse Events*

- Adverse Events, Internal:
 - > unexpected, and
 - related or possibly related, and
 - serious <u>OR</u> suggest new/increased risk
- Adverse Events, External:
 - unexpected, and
 - related or possibly related, and
 - serious <u>OR</u> suggest new/increased risk, and
 - warrant a change to the protocol, subject notification, or re-consent

* Includes unanticipated adverse device effect





New Safety "Findings"



- Interim analysis
- DSMB report
- Findings from related studies
- Hold or early closure due to safety concerns



Protocol Deviations





Noncompliance

Conduct research without IRB approval or exemption

- Start before approval letter received
- During a lapse in approval
- Fail to obtain informed consent or to re-consent w/ new risk
- Deviate from the approved consent or recruitment process
- Initiate changes to the protocol without IRB approval
- Fail to complete required human subjects protection training
- Over-enroll in a study that is greater than minimal risk



"Other" New Safety Information

- Breach or potential breach of confidentiality or privacy
- Subject complaint
 - Rights, welfare, or safety adversely affected, or
 - Cannot be resolved by the investigator
- Incarceration of subject in study not approved to include prisoners
- Audit, inspection, or written report by a federal agency (FDA 483)
- State board action (e.g., suspension of professional license)
 - > Affects the ability to conduct the study as approved, *or*
 - Increases risks to subjects or others



New Safety Information -UNC cedes review

- Unanticipated Problem Involving Risk to Subjects or Others (UPIRSO) determination *when the event involved UNC subjects or researchers*
- Serious Noncompliance determination when the event involved UNC subjects or researchers
- Continuing Noncompliance determination when the event involved UNC subjects or researchers
- Suspension
- Termination




When to Report?



*Calendar days



Flow of Information



UNC RESEARCH

Who is SWAG?









Safety Welfare Analysis Group (SWAG)

- Reviews all New Safety Information
- Includes ≥ 3 members who have experience with research
 - Vicki Bae-Jump, MD, PhD, Associate Professor OBGYN-GynOnc , LCCC
 - Luigi Troiani, PA, Clinical Instructor, Department of Neurology
 - Jeanne Lovmo, MA, OHRE Compliance Manager
- This is NOT an IRB



SWAG's Review Process

- Requests additional information
- Evaluates information
- Works with Investigators to Develop Sufficient Corrective and Preventative Actions (CAPA) Plans
- Resolves submission that does not represent UPIRSO, Serious or Continuing Noncompliance.
- Refers information to Safety Committee.





Who is the Safety Committee?

Serves as an IRB in accordance with 45 CFR 46, and 21 CFR 50 and 56 (SOP 401).

- At least five members of varying backgrounds who are qualified through experience and expertise
- One scientist, one nonscientist, one unaffiliated member, one member who represents the general perspective of a participant





Regulatory Determinations

- Serious Noncompliance (SNC)
- Continuing Noncompliance (CNC)
- Unanticipated Problem Involving Risk to Subjects or Others (UPIRSO)
- Suspension of IRB Approval
- Termination of IRB approval



Considerations

- Modification of protocol and/or consent document
- Reconsent, Notification
- Modification of continuing review schedule
- Additional monitoring or training
- If suspension/termination participant transfer, refer for care outside study, followup continue under independent monitoring
- Additional resources to support the research recommended/required?
- Recommendations for the Vice Chancellor for Research (IO)





PI NotificationDetermination(s)

- Rationale for the determination(s)
- Any actions requested and recommended by the committee.





IRB Reporting Requirement to Federal Agencies



FDA Regulated Research



Federally Funded Research

[45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]





